Managing the underestimated risk of statin-associated myopathy
Authors:
- Loukianos S. RallidisLRLoukianos S. Rallidis
- Katerina FountoulakiKFKaterina Fountoulaki
- Maria Anastasiou-NanaMAMaria Anastasiou-Nana
- 1 September 2012
- journal article
- review article
- Published by Elsevier in International Journal of Cardiology
- Vol. 159 (3) , 169-176
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-upExpert Opinion on Pharmacotherapy, 2011
- Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countriesCurrent Medical Research and Opinion, 2009
- Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countriesThe Lancet, 2009
- Risks Associated With Statin TherapyCirculation, 2006
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group RecommendationsThe American Journal of Cardiology, 2005
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995